Literature DB >> 16019093

Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study.

Dirk De Ruysscher1, Stofferinus Wanders, Andre Minken, Aniek Lumens, Jacqueline Schiffelers, Cissie Stultiens, Serve Halders, Liesbeth Boersma, Angela van Baardwijk, Tom Verschueren, Monique Hochstenbag, Gabriel Snoep, Brad Wouters, Sebastiaan Nijsten, Søren M Bentzen, Marinus van Kroonenburgh, Michel Ollers, Philippe Lambin.   

Abstract

BACKGROUND AND
PURPOSE: To investigate the effect of radiotherapy planning with a dedicated combined PET-CT simulator of patients with locally advanced non-small cell lung cancer. PATIENTS AND METHODS: Twenty-one patients underwent a pre-treatment simulation on a dedicated hybrid PET-CT-simulator. For each patient, two 3D conformal treatment plans were made: one with a CT based PTV and one with a PET-CT based PTV, both to deliver 60Gy in 30 fractions. The maximum tolerable prescribed radiation dose for CT versus PET-CT PTV was calculated based on constraints for the lung, the oesophagus, and the spinal cord, and the Tumour Control Probability (TCP) was estimated.
RESULTS: For the same toxicity levels of the lung, oesophagus and spinal cord, the dose could be increased from 55.2+/-2.0Gy with CT planning to 68.9+/-3.3Gy with the use of PET-CT (P=0.002), with corresponding TCP's of 6.3+/-1.5% for CT and 24.0+/-5.6% for PET-CT planning (P=0.01).
CONCLUSIONS: The use of a combined dedicated PET-CT-simulator reduced radiation exposure of the oesophagus and the lung, and thus allowed significant radiation dose escalation whilst respecting all relevant normal tissue constraints.

Entities:  

Mesh:

Year:  2005        PMID: 16019093     DOI: 10.1016/j.radonc.2005.06.014

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  25 in total

1.  Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer.

Authors:  Andre Konski; Tianyu Li; Michael Christensen; Jonathan D Cheng; Jian Q Yu; Kevin Crawford; Oleh Haluszka; Jeffrey Tokar; Walter Scott; Neal J Meropol; Steven J Cohen; Alan Maurer; Gary M Freedman
Journal:  Radiother Oncol       Date:  2012-06-07       Impact factor: 6.280

2.  Use of a diagnostic positron emission tomography-computed tomography system for planning radiotherapy positioning: distortion of the tabletop.

Authors:  Yoshiomi Kishida; Hitoshi Ikushima; Motoharu Sasaki; Yasuo Hara; Masataka Oita; Hiromu Nishitani
Journal:  Jpn J Radiol       Date:  2010-02-26       Impact factor: 2.374

Review 3.  The use of FDG-PET to target tumors by radiotherapy.

Authors:  Guido Lammering; Dirk De Ruysscher; Angela van Baardwijk; Brigitta G Baumert; Jacques Borger; Ludy Lutgens; Piet van den Ende; Michel Ollers; Philippe Lambin
Journal:  Strahlenther Onkol       Date:  2010-08-30       Impact factor: 3.621

Review 4.  Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription.

Authors:  Søren M Bentzen; Vincent Gregoire
Journal:  Semin Radiat Oncol       Date:  2011-04       Impact factor: 5.934

Review 5.  The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy.

Authors:  Richard L Wahl; Joseph M Herman; Eric Ford
Journal:  Semin Radiat Oncol       Date:  2011-04       Impact factor: 5.934

6.  Conventional 3D staging PET/CT in CT simulation for lung cancer: impact of rigid and deformable target volume alignments for radiotherapy treatment planning.

Authors:  G G Hanna; J R Van Sörnsen De Koste; K J Carson; J M O'Sullivan; A R Hounsell; S Senan
Journal:  Br J Radiol       Date:  2011-01-11       Impact factor: 3.039

Review 7.  Anatomic, functional and molecular imaging in lung cancer precision radiation therapy: treatment response assessment and radiation therapy personalization.

Authors:  Michael MacManus; Sarah Everitt; Tanja Schimek-Jasch; X Allen Li; Ursula Nestle; Feng-Ming Spring Kong
Journal:  Transl Lung Cancer Res       Date:  2017-12

8.  Evaluation of the Metabolic Response to Cyclopamine Therapy in Pancreatic Cancer Xenografts Using a Clinical PET-CT System.

Authors:  Hany Kayed; Patrick Meyer; Yong He; Bettina Kraenzlin; Christian Fink; Norbert Gretz; Stefan O Schoenberg; Maliha Sadick
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

Review 9.  Biologically conformal treatment: biomarkers and functional imaging in radiation oncology.

Authors:  Yaacov Richard Lawrence; Maria Werner-Wasik; Adam P Dicker
Journal:  Future Oncol       Date:  2008-10       Impact factor: 3.404

10.  Current concepts on imaging in radiotherapy.

Authors:  Michela Lecchi; Piero Fossati; Federica Elisei; Roberto Orecchia; Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-31       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.